ArticleBMC infectious diseases2026
Cytomegalovirus reactivation prevention and treatment post-hematopoietic stem cell transplantation: a Delphi study in four Gulf cooperation council countries.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThese Delphi recommendations aimed to establish regional consensus for the effective management of Cytomegalovirus (CMV) reactivation/infection and CMV disease following allogeneic hematopoietic stem cell transplantation (alloHSCT).
methodA modified Delphi approach, comprising three rounds of anonymous questionnaires with field experts, was used. The first round included open-ended questions to identify and prioritize key topics, while the subsequent rounds focused on refining responses and reaching a consensus. A predefined consensus threshold of 70% agreement among panelists was used.
resultsAfter two rounds, a consensus was reached on 21 key questions related to the diagnosis and management of CMV reactivation and CMV disease post-alloHSCT. The panel identified these areas as priorities for future research or guideline refinement.
conclusionThis Delphi study successfully established an expert consensus on pre-emptive therapy and prophylactic treatment for managing CMV reactivation and treatment strategies for CMV disease. The study findings, based on inputs from experts related to clinical practices in the region, can serve as an additional tool for clinical decision-making. Moreover, the panelists highlighted the unmet need for harmonizing diagnostic practices and thresholds among hematology centers in the Gulf region. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.